Highlights of weekly biotech stock moves

Durect Corp. (NASDAQ:DRRX) was off $0.42 (12%) to $3.17 on Tuesday after partner Pfizer Inc. (NYSE:PFE) said that the approval or launch of pain candidate Remoxy could be delayed by an undisclosed issue in the manufacturing section of the application, as well as by FDA's recently announced classwide REMS for extended-release and long-acting opioids. The NDA has a June 23 PDUFA date.

Pfizer has rights from Pain Therapeutics Inc. (NASDAQ:PTIE). The product uses Oradur technology from Durect, which lost $0.48 (13%) to $3.25 on the week, while Pain was off $0.93 (10%) to $8.58...